ADAMAS PHARMACEUTICALS Forum: Community User: Wernner

Ich hatte auch Anfang des Jahres verkauft, hoffe noch auf einen Rücksetzer zum Wiedereinstieg, was sind die Meilensteine bis Jahresende!?

https://www.insidermonkey.com/blog/hedge-funds-are-dumping-adamas-pharmaceuticals-inc-adms-763698/

Hab mich ja nach dem großen Anstieg vor längerer Zeit ausgeklingt und bin seit einigen Monaten wieder dabei... dank einer größeren posi zu knapp 4 Euro ist mein EK in Reichweite. adamas hat noch einiges in der pipeline und gehe davon aus, dass jetzt erstmal positive news folgen.

War nie weg Nerfi.

@Moma: bist du hier wieder dabei?

Eigentlich müsste der Boden gefunden sein... adamas hat auch noch etwas in der pipeline... gute news könnte man bei dem kursniveau echt gebrauchen.

Steigt weiter 😀

Nach aktuellem stand war es eine gute Idee bei 4 Euro nachgekauft zu haben.

Über die 6$ Marke wieder. 😁

nix für Schwäche nerven hier.

Was ist los mit der rumpelbude

Adamas, incorporated in Delaware and headquartered in Emeryville, California, is a commercial stage pharmaceutical company that specializes in developing drug treatment therapies for chronic neurologic disorders. Adamas’s primary product is GOCOVRI, an extended-release formulation of amantadine (formerly referred to as ADS-5102), which has been approved by the U.S. Food and Drug Administration for the treatment of levodopa-induced dyskinesia. The action alleges the SPO registration statement and prospectus (collectively, the “Offering Documents”) contained untrue statements and/or omitted material facts required to be stated or necessary to make statements therein not misleading. Specifically, the action alleges that Adamas *** materially false and misleading statements in the Offering Documents about known risks and trends that would dramatically reduce its ability to sell GOCOVRI, including: (i) that insurers required physicians to obtain prior authorization before prescribing the drug; (ii) that insurers required physicians to prescribe cheaper generic alternatives before seeking prior authorization; (iii) that GOCOVRI is exorbitantly more expensive than its generic alternatives; and (iv) that physicians were ambivalent about GOCOVRI’s efficacy. Through its SPO, Adamas sold approximately 3.45 million shares of its common stock to the investing public at $41.50 per share. On October 5, 2018, Merrill Lynch released a study of physicians and subscribers that cast serious doubt on GOCOVRI’s ability to achieve a sizeable market share, and it specifically identified a number of facts that rendered the Company’s statements in the Offering Documents false or misleading. On March 4, 2019, Adamas walked back its previous growth estimates for GOCOVRI, warned of a continued slow-down in prescriptions, and refused to make further predictions about GOCOVRI’s ability to achieve a sizeable market share. On this news, Adamas’s stock fell $3.99 per share, to close at $8.16 per share on March 5, 2019, capping off a decline of over 80% in the year following the SPO. About Lieff Cabraser Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility. The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms “representing the best qualities of the plaintiffs’ bar and that demonstrated unusual dedication and creativity.” Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm’s “laser focus” and noting that our firm routinely finds itself “facing off against some of the largest and strongest defense law firms in the world.” In late 2016, Benchmark Litigation named Lieff Cabraser one of the “Top 10 Plaintiffs’ Firms in America.”

Denke bis Ende Juni ist der Boden gefunden, überlege dann wieder eine Position aufzubauen...

EMERYVILLE, Calif., June 07, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 148,500  shares of the company’s common stock, at a per share exercise price of $4.67, the closing trading price on June 7, 2019, and restricted stock units to acquire 74,250 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company. About Adamas Pharmaceuticals, Inc. Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The Company is focused on the commercialization of GOCOVRI® (amantadine) extended release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. The Company also continues to deliver differentiated investigational programs, including ADS-5102 in development for the treatment of walking impairment in patients with multiple sclerosis. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com. 

allzeittief

Börse kann so brutal sein... was würde adamas gepusht und erreicht haben se nichts, bis auf ein paar Kröten Umsatz. marktkapitalisierung ist ein Witz.